---
input_text: "The use Prometheus FPSA system in the treatment of acute liver failure:
  preliminary results. UNLABELLED: The preliminary outcomes of patients with acute
  liver failure treated with the Prometheus Fractionated Plasma Separation and Absorption
  (FPSA) system are presented herein. PATIENTS AND METHODS: The procedures were performed
  in 13 patients (4, intoxication by Amanita phalloides; 4, unknown reason; 3, acetaminophen
  intoxication; 1, Wilson disease, and 1, liver insufficiency after hemihepatectomy
  owing to metastases of colon adenocarcinoma). The patients were qualified for the
  procedure according to the King's College Hospital criteria. The patients' general
  status was assessed on basic of GCS, UNOS, and the 4-grade encephalopathy classifications.
  The procedures were performed with the Prometheus 4008H Fresenius Medical Care unit.
  RESULTS: The 29 procedures were of mean duration 6.5 hours. There were statistically
  significant reductions in total bilirubin, ammonia, and aminotransferase levels.
  In addition, the procedures corrected water, mineral, and carbohydrate disorders.
  One patient did not require liver transplantation. Seven patients received liver
  transplants: three patients with positive outcomes; two died due to septicemia within
  30 days perioperatively, one died at 6 months after OLT owing to respiratory failure;
  and one, owing to hemorrhagic diathesis. Four patients did not receive a liver transplant
  because of lack of a organ, no consent for the surgery, or neoplastic disease with
  metastases. CONCLUSIONS: The Prometheus FPSA-System was an effective detoxication
  method for patients with acute liver failure. The system was useful as a symptomatic
  treatment before liver transplantation allowing a longer wait for a graft."
raw_completion_output: |-
  primary_disease: Acute liver failure

  medical_actions: Prometheus Fractionated Plasma Separation and Absorption (FPSA) system; Liver transplantation

  symptoms: High total bilirubin; High ammonia; High aminotransferase levels; Water disorders; Mineral disorders; Carbohydrate disorders; Encephalopathy

  chemicals: 

  action_annotation_relationships: Prometheus Fractionated Plasma Separation and Absorption (FPSA) system TREATS high total bilirubin IN acute liver failure; Prometheus Fractionated Plasma Separation and Absorption (FPSA) system TREATS high ammonia IN acute liver failure; Prometheus Fractionated Plasma Separation and Absorption (FPSA) system TREATS high aminotransferase levels IN acute liver failure; Prometheus Fractionated Plasma Separation and Absorption (FPSA) system TREATS water disorders IN acute liver failure; Prometheus Fractionated Plasma Separation and Absorption (FPSA) system TREATS mineral disorders IN acute liver failure; Prometheus Fractionated Plasma Separation and Absorption (FPSA) system TREATS carbohydrate disorders IN acute liver failure; Liver transplantation TREATS acute liver failure
prompt: |+
  Split the following piece of text into fields in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Liver transplantation TREATS acute liver failure

  ===

extracted_object:
  primary_disease: MONDO:0019542
  medical_actions:
    - Prometheus Fractionated Plasma Separation and Absorption (FPSA) system
    - MAXO:0001175
  symptoms:
    - High total bilirubin
    - High ammonia
    - High aminotransferase levels
    - Water disorders
    - Mineral disorders
    - Carbohydrate disorders
    - HP:0001298
  action_annotation_relationships:
    - subject: <Prometheus FPSA system>
      predicate: <TREATS>
      object: <high total bilirubin>
      qualifier: <acute liver failure>
      subject_qualifier: <>
      object_qualifier: <>
      subject_extension: <Fractionated Plasma Separation and Absorption>
      object_extension: <>
    - subject: Prometheus Fractionated Plasma Separation and Absorption (FPSA) system
      predicate: TREATS
      object: high ammonia
      qualifier: MONDO:0019542
    - subject: Prometheus Fractionated Plasma Separation and Absorption (FPSA) system
      predicate: TREATS
      object: high aminotransferase levels
      qualifier: MONDO:0019542
      subject_extension: Fractionated Plasma Separation and Absorption (FPSA) system
    - subject: Prometheus Fractionated Plasma Separation and Absorption (FPSA) system
      predicate: TREATS
      object: water disorders
      qualifier: MONDO:0019542
      subject_extension: Fractionated Plasma Separation and Absorption (FPSA) system
    - subject: Prometheus Fractionated Plasma Separation and Absorption (FPSA) system
      predicate: TREATS
      object: mineral disorders
      qualifier: MONDO:0019542
      subject_extension: Fractionated Plasma Separation and Absorption (FPSA)
    - subject: Prometheus Fractionated Plasma Separation and Absorption (FPSA) system
      predicate: TREATS
      object: carbohydrate disorders
      qualifier: MONDO:0019542
      subject_extension: Fractionated Plasma Separation and Absorption (FPSA)
      object_extension: carbohydrate disorders
    - subject: MAXO:0001175
      predicate: TREATS
      object: HP:0006554
named_entities:
  - id: MONDO:0010200
    label: Wilson's disease
  - id: MAXO:0001175
    label: Liver transplantation
  - id: HP:0001695
    label: Cardiac arrest
  - id: HP:0001685
    label: Myocardial fibrosis
  - id: HP:0001663
    label: Ventricular fibrillation
  - id: CHEBI:28694
    label: Copper
  - id: CHEBI:18248
    label: Iron
  - id: HP:0002910
    label: abnormal liver functions
  - id: HP:0001394
    label: cirrhosis
  - id: CHEBI:27363
    label: zinc
  - id: CHEBI:50868
    label: penicillamine
  - id: MAXO:0000016
    label: Cell therapy
  - id: MAXO:0001001
    label: Gene therapy
  - id: CHEBI:30703
    label: Tetrathiomolybdate (TTM)
  - id: HP:0006554
    label: acute liver failure
  - id: CHEBI:35176
    label: Zinc sulphate
  - id: CHEBI:35475
    label: NSAIDs
  - id: MAXO:0009095
    label: zinc therapy
  - id: MAXO:0001298
    label: therapy
  - id: HP:0006579
    label: neonatal jaundice
  - id: HP:0001409
    label: portal hypertension
  - id: HP:0030151
    label: cholangitis
  - id: HP:0002612
    label: congenital hepatic fibrosis
  - id: MONDO:0013282
    label: alpha-1-antitrypsin deficiency
  - id: HP:0001903
    label: anemia
  - id: HP:0001410
    label: liver dysfunction
  - id: CHEBI:39501
    label: trientine
  - id: MAXO:0000070
    label: Hepatic transplantation
  - id: HP:0001399
    label: Hepatic failure
  - id: HP:0004448
    label: fulminant hepatic failure
  - id: HP:0003256
    label: coagulopathy (international normalized ratio >2.0)
  - id: HP:0004445
    label: hepatic encephalopathy (HE)
  - id: HP:0002480
    label: hepatic encephalopathy
  - id: CHEBI:35341
    label: Steroids
  - id: CHEBI:33281
    label: Antibiotics
  - id: MONDO:0100193
    label: End-stage liver disease
  - id: HP:0100626
    label: End-stage liver disease
  - id: HP:0100660
    label: dyskinesia
  - id: HP:0100022
    label: Movement disorders
  - id: HP:0001337
    label: Tremor
  - id: HP:0001332
    label: Dystonia
  - id: MONDO:0019542
    label: Acute liver failure (ALF)
  - id: CHEBI:27385
    label: CCL4
  - id: MAXO:0000127
    label: Genetic testing
  - id: CHEBI:7959
    label: D-penicillamine
  - id: MAXO:0001017
    label: Vaccination
  - id: HP:0001541
    label: Ascites
  - id: HP:0012398
    label: Peripheral edema
  - id: HP:0001260
    label: dysarthria
  - id: HP:0000708
    label: psychiatric disorders
  - id: HP:0200123
    label: chronic hepatitis
  - id: CHEBI:38161
    label: chelators
  - id: MAXO:0000376
    label: liver biopsy
  - id: HP:0001404
    label: hepatocellular necrosis
  - id: CHEBI:61049
    label: Tacrolimus
  - id: HP:0001744
    label: Splenomegaly
  - id: MAXO:0000603
    label: Peritoneal dialysis
  - id: HP:0200032
    label: Kayser-Fleischer rings
  - id: HP:0002172
    label: impaired balance
  - id: HP:0001347
    label: hyperreflexia
  - id: HP:0031843
    label: bradyphrenia
  - id: HP:0002362
    label: shuffling gait
  - id: HP:0001621
    label: hypophonia
  - id: CHEBI:37153
    label: Calcineurin inhibitors
  - id: CHEBI:8356
    label: pramipexole
  - id: CHEBI:2618
    label: amantadine
  - id: HP:0000093
    label: proteinuria
  - id: CHEBI:231592
    label: zinc salts
  - id: MAXO:0000167
    label: antiepileptic therapy
  - id: CHEBI:9168
    label: rapamycin
  - id: CHEBI:55379
    label: cyclosporine (CsA)
  - id: CHEBI:35623
    label: antiepileptic
  - id: HP:0000083
    label: renal failure
  - id: HP:0000952
    label: jaundice
  - id: HP:0001919
    label: acute kidney injury
  - id: HP:0001342
    label: intracerebral hemorrhage
  - id: MAXO:0000533
    label: molecular genetic testing
  - id: HP:0001873
    label: thrombocytopenia
  - id: HP:0001298
    label: Encephalopathy
  - id: MAXO:0009070
    label: SPECT
  - id: HP:0001251
    label: ataxia
  - id: CHEBI:166831
    label: copper chelators
  - id: MAXO:0035064
    label: electron microscopic studies
  - id: MAXO:0000139
    label: autopsy
  - id: HP:0006577
    label: macronodular cirrhosis
  - id: CHEBI:8830
    label: rhodanine
  - id: HP:0001272
    label: Cerebellar Atrophy
  - id: HP:0007263
    label: Spinocerebellar Ataxia
  - id: MAXO:0001610
    label: transcranial magnetic stimulation
  - id: HP:0002015
    label: dysphagia
  - id: HP:0001392
    label: liver disease
  - id: HP:0001396
    label: cholestasis
  - id: HP:0001403
    label: macrovesicular steatosis
  - id: CHEBI:90299
    label: orcein
  - id: MONDO:0000437
    label: Spinocerebellar degeneration
  - id: CHEBI:2948
    label: Azathioprine
  - id: CHEBI:8378
    label: Prednisolone
  - id: HP:0031690
    label: opportunistic infections
  - id: HP:0001397
    label: Steatosis
  - id: HP:0001513
    label: Obesity
  - id: HP:0000819
    label: Diabetes
  - id: HP:6000457
    label: Mallory bodies
  - id: HP:0002829
    label: Arthralgia
  - id: CHEBI:9907
    label: Ursodeoxycholic acid
  - id: MONDO:0007027
    label: Non-alcoholic steatohepatitis (NASH)
  - id: MONDO:0006507
    label: Hereditary hemochromatosis (HH)
  - id: MONDO:0018874
    label: Acute Myeloid Leukemia (AML)
  - id: CHEBI:41977
    label: Daunorubicin
  - id: CHEBI:28680
    label: Cytarabine
  - id: HP:0004808
    label: Acute Myeloid Leukemia (AML)
  - id: CHEBI:16856
    label: Glutathione (GSH)
  - id: CHEBI:53498
    label: Total antioxidant capacity (TAC)
  - id: CHEBI:566274
    label: Malondialdehyde (MDA)
  - id: HP:0001289
    label: Confusion
  - id: CHEBI:46195
    label: Acetaminophen
  - id: HP:0000989
    label: itchy skin
  - id: CHEBI:63623
    label: dimercaptosuccinic acid
  - id: CHEBI:145810
    label: insulin
  - id: MONDO:0003441
    label: dystonia
  - id: MAXO:0009015
    label: botulinum toxin injection
  - id: MAXO:0000943
    label: deep brain stimulation
  - id: HP:0004305
    label: involuntary movements
  - id: CHEBI:9720
    label: trihexyphenidyl
  - id: CHEBI:35474
    label: minor tranquilizers
  - id: HP:0005268
    label: spontaneous abortion
  - id: HP:0100520
    label: oliguria
  - id: CHEBI:16737
    label: creatinine
  - id: HP:0100543
    label: Cognitive impairment
  - id: HP:0001250
    label: epileptic seizures
  - id: HP:0002315
    label: headache
  - id: CHEBI:6437
    label: levetiracetam
  - id: HP:0002878
    label: Acute respiratory failure
  - id: MONDO:0004789
    label: Cholangitis
  - id: CHEBI:33234
    label: Vitamin E
  - id: HP:0001953
    label: diabetic ketoacidosis (DKA)
  - id: HP:0001942
    label: metabolic acidosis
  - id: HP:0001946
    label: ketosis
  - id: HP:0003781
    label: Hypersalivation
  - id: HP:0002027
    label: Abdominal pain
  - id: HP:0002240
    label: Hepatomegaly
  - id: HP:0000707
    label: neurologic abnormalities
  - id: CHEBI:16796
    label: Melatonin
  - id: HP:0011967
    label: copper deficiency
  - id: HP:0100785
    label: Insomnia
  - id: HP:0003394
    label: Muscle cramps
  - id: HP:0003401
    label: Paresthesia
  - id: HP:0025406
    label: Weakness
  - id: CHEBI:4031
    label: Cyclosporine
  - id: CHEBI:8764
    label: Mycophenolate mofetil
  - id: MONDO:0019737
    label: Thrombotic microangiopathy (TMA)
